Rating Change
Leerink Partners analysts initiated coverage on Ligand Pharmaceuticals, Inc. (OTC:LGNDZ) with a rating of Outperform on August 14, 2026.
new coverageOTC:LGNDZ
Leerink Partners Initiates Coverage on Ligand Pharmaceuticals, Inc. (LGNDZ) with Outperform
Leerink Partners analysts initiated coverage on Ligand Pharmaceuticals, Inc. (OTC:LGNDZ) with a rating of Outperform on August 14, 2026.
At publication ·
What changed
Ligand Pharmaceuticals, Inc. (OTC:LGNDZ) · new coverage
- Firm
- Leerink Partners
- Rating
- Outperform
- Price at event
- $0.00
- Market capitalization
- $157.5K
At a glance
Key takeaways
- Leerink Partners initiated coverage of Ligand Pharmaceuticals (LGNDZ) with an Outperform rating on August 14, 2026.
- The stock trades at $0.00 with a market capitalization of $157.5K and has declined 78.9% over the past 52 weeks.
Market Context
Ligand Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $0.00 with a market capitalization of $157.5K. The stock has declined 78.9% over the past 52 weeks.
Analyst coverage from Leerink Partners provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Ligand Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Ligand Pharmaceuticals, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 14, 2026 | Leerink Partners | Outperform | N/A |
| Aug 07, 2026 | RBC Capital | Outperform | N/A |
| Aug 06, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 03, 2026 | Oppenheimer | Outperform | N/A |
| Jul 21, 2026 | Citigroup | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View LGNDZ Stock Page
Frequently Asked Questions
What does the Outperform rating mean for LGNDZ?
A rating of Outperform from Leerink Partners reflects the analyst's outlook on Ligand Pharmaceuticals, Inc. (OTC:LGNDZ). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the LGNDZ forecast page.
